Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals [Yahoo! Finance]
Aerovate Therapeutics, Inc. (AVTE)
Company Research
Source: Yahoo! Finance
from the mid-stage portion of the IIb/III IMPAHCT study evaluating its lead candidate, AV-101, in adults with pulmonary arterial hypertension (PAH). The mid to late-stage IMPAHCT study evaluated the efficacy, safety and tolerability of three different doses of AV-101 compared with placebo. Per the data readout from the phase IIb portion of the IMPAHCT study, AV-101, a novel dry powder inhaled formulation of imatinib, failed to meet the primary endpoint of change in pulmonary vascular resistance for any of the studied doses. Moreover, treatment with the candidate did not demonstrate any meaningful improvements in the study's secondary endpoint of change in the six-minute walk distance. The company has further reviewed data from several additional secondary endpoints of the phase IIb portion of the IMPAHCT study and found no meaningful improvements. Based on such poor outcomes, AVTE has decided, in agreement with the independent study advisory committee, to halt enrollment and s
Show less
Read more
Impact Snapshot
Event Time:
AVTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVTE alerts
High impacting Aerovate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AVTE
Earnings
- 8/12/24 - Miss
AVTE
Sec Filings
- 8/12/24 - Form 10-Q
- 8/2/24 - Form 4
- 7/8/24 - Form 8-K
- AVTE's page on the SEC website